SEC Filings
Sanofi Ends Trial Of STAT6 Degrader, Wiping Out Nurix's Milestone And Royalty Prospects On It
Nurix remains eligible for payments on other licensed programs in its Sanofi collaboration, which Sanofi may develop at its discretion.
NRIX
Nurix Therapeutics (NRIX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Nurix's 10-Q Books $653.2 Million Of Roche's $700 Million Upfront As License Revenue, Flipping A Nine-Month Loss To Profit
The swing to $373.1 million in nine-month net income is mostly one license booking, and the filing adds a California tax charge and cost-sharing duties.
SEC Filings
Nurix Posts $549.8 Million Quarterly Profit After Roche Collaboration Revenue, Against An $86.4 Million Loss
Revenue reached $673.1 million in the quarter ended August 31, and the company says $1.1 billion in cash lasts into the second half of 2029.